newsfilter
← Latest News
GlobeNewswire·

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection)